Can an IDO1 inhibitor boost immunotherapy against liver cancer?
NCT ID NCT03695250
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial is testing whether combining an experimental IDO1 inhibitor (BMS-986205) with the immunotherapy drug nivolumab can shrink tumors or slow disease progression in people with advanced liver cancer that cannot be surgically removed. The study enrolls adults whose cancer has not responded to or has progressed after prior treatment. Researchers are evaluating safety, the best dose, and how well the combination works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an IDO1 inhibitor called BMS-986205 combined with the immunotherapy nivolumab (Opdivo)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced liver cancer who have limited alternatives.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the benefits and risks are not yet well understood. Side effects from the drug combination may occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI takes on liver cancer: could a computer help pick the right immunotherapy?
- 3D MRI scan may predict liver cancer treatment success
- New scan could spot hidden cancer left behind after liver surgery
- 3D liver stiffness scan could predict surgery risks
- Immunotherapy combo tested against untreatable liver cancer
- New drug zanzalintinib tested for advanced liver cancer